RESEARCH ARTICLE


Efficacy and Safety of Miglitol: Switching Study from Voglibose in Japanese Patients with Type 2 Diabetes



Sachiko Honjo1, Hiroki Ikeda*, 1, Yukiko Kawasaki1, Yoshiharu Wada1, Yoshiyuki Hamamoto2, Tomohisa Aoyama1, Tetsuya Kimura1, Kazuhiro Nomura1, Hiroyuki Koshiyama1
1 Center for Diabetes and Endocrinology, the Tazuke Kofukai Medical Research Institute Kitano Hospital, Japan.
2 Department of Diabetes & Clinical Nutrition, Graduate School of Medicine, Kyoto University, Japan/

Article Information


Identifiers and Pagination:

Year: 2009
Volume: 2
First Page: 60
Last Page: 61
Publisher Id: TODIAJ-2-60
DOI: 10.2174/1876524600902010060

Article History:

Received Date: 17/04/2009
Revision Received Date: 11/05/2009
Acceptance Date: 29/07/2009
Electronic publication date: 31/8/2009
Collection year: 2009

© Honjo et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Correspondence: *Address correspondence to this author at the Center for Diabetes & Endocrinology, Medical Institute Kitano Hospital, 2-4-20 Ohgi-machi, Kitaku Osaka, 530-8480, Japan; Tel: +81-6-6312-8824; Fax: +81-6-6361-8867; E-mails: hirk0913@yahoo.co.jp,a-ikeda@kitano-hp.or.jp


Abstract

We investigated the efficacy and safety of miglitol, a new alpha-glucosidase inhibitor, by switching from voglibose in Japanese patients with type 2 diabetes. Subjects included those who had previously been administered with voglibose (n=90, 0.6mg/day). After voglibose was changed into miglitol (150mg/day), HbA1C level, body weight and abdominal symptoms were evaluated six months later. HbA1C level was significantly decreased from 7.8±1.2 to 7.3±1.0% (P<0.01). Body weight showed a small but significant decrease after 6 months (62.5±11.0 to 62.1±12.3kg, P<0.01). There was no significant difference between frequencies of side effects before and after switching from voglibose to miglitol. This study suggests the efficacy and safety of miglitol to improve glycemic control in Japanese patients with type 2 diabetes, who had previously been treated with voglibose.

Keywords: